NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/12/2022
Voltar para busca
Dado oficial do USPTO
HELIUS THERAPEUTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
HELIUS THERAPEUTICS
ST13
US500000079285864Classe
1, 5, 35, 44
Pedido
79285864
Registro
6578319
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
47
Atualização mais recente
02/12/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 35, 44
Data de depósito
18/12/2019
Data de registro
07/12/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/12/2021
Última transação
07/12/2021
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
NZ
Examinador
STRUCK, ROBERT J
Unidade examinadora
L90
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
HELIUS THERAPEUTICS LIMITED
HELIUS THERAPEUTICS LIMITED
Representantes
Sarah P. Harrell BARNES & THORNBURG LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 35Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Active chemical ingredients for use in the manufacture of pharmaceuticals solely derived from cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis and not containing CBD
Classe 5
Pharmaceutical preparations for the treatment of painappetite lossepilepsy and seizuresglaucomasleep disordersmuscle spasmsnauseagastrointestinal disorderscancerAlzheimer's diseasesymptoms of post-traumatic stress disorderanxietydepressionschizophreniaaddiction disorderinflammationmultiple sclerosispre-menstrual syndrome; medicinal preparations for the treatment of painappetite lossepilepsy and seizuresglaucomasleep disordersmuscle spasmsnauseagastrointestinal disorderscancerAlzheimer's diseasesymptoms of post-traumatic stress disorderanxietydepressionschizophreniaaddiction disorderinflammationmultiple sclerosispre-menstrual syndrome; herbal preparations and extracts for medicinal use; medical cannabis and derivatives thereof namelymedicinal herbs and medicinal herb extracts; herbal supplements; all of the foregoing containing or solely derived from cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis and not containing CBD
Classe 35
Retail and wholesale store services featuring cannabis medicinal herbscannabis oil and derivatives thereof all of the foregoing containing or solely derived from cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis and not containing CBD; retail and wholesale store services featuring hemp and cannabis cosmetic products and accessoriesfood productsbeveragespersonal care preparationsskin care preparationsall of the foregoing containing or solely derived from cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis and not containing CBD; providing consumer information featuring the ratingsreviews and recommendations on marijuana and medical marijuana products via a website
Classe 44
Cultivation of plants for others featuring solely cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; consultancy services relating to the cultivation of plants; cultivation and breeding for others of cannabis all of the foregoing containing or solely derived from cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; providing health and agricultural information in the field of medical marijuana and cannabis via a website; providing medical information featuring indications and effects of particular cannabis strainsthe benefits of medical marijuanamarijuanacannabis and research related to cannabis and marijuana via a website
Publicações
Histórico de despachos e eventos da marca no USPTO.
47 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/07/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
23/05/2022
FIMP
FINAL DISPOSITION PROCESSED
23/05/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/03/2022
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
08/01/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
18/12/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
07/12/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
14/11/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
27/10/2021
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
27/10/2021
GPNX
NOTIFICATION PROCESSED BY IB
04/10/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/09/2021
PUBO
PUBLISHED FOR OPPOSITION
21/09/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/09/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/09/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/09/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
19/08/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
16/08/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/08/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
12/08/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/08/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
15/07/2021
ALIE
ASSIGNED TO LIE
15/07/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
15/07/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
15/07/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
15/07/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/06/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/06/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
04/06/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
29/04/2021
GNFR
FINAL REFUSAL E-MAILED
29/04/2021
CNFR
FINAL REFUSAL WRITTEN
29/04/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/03/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/03/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/03/2021
RFNT
REFUSAL PROCESSED BY IB
18/10/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
30/09/2020
RFRR
REFUSAL PROCESSED BY MPU
30/09/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/09/2020
CNRT
NON-FINAL ACTION WRITTEN
09/09/2020
DOCK
ASSIGNED TO EXAMINER
09/09/2020
MAFR
APPLICATION FILING RECEIPT MAILED
02/06/2020
DOCK
ASSIGNED TO EXAMINER
28/05/2020
DOCK
ASSIGNED TO EXAMINER
27/05/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
27/05/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
21/05/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace HELIUS THERAPEUTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.